www.directintegrativecare.com

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Endometriosis is increasingly recognized as a chronic, systemic, estrogen-driven inflammatory condition rather than a simple pelvic problem. It affects roughly one in ten women of reproductive age, takes an average of 7–10 years to diagnose, and carries a profound burden on pain, fertility, mental health, and quality of life. ^[1] For a disease this complex, no single intervention—whether surgical, pharmacological, or naturopathic—is sufficient on its own. The strongest evidence supports a multidisciplinary, integrative model in which conventional gynecologic treatment serves as the backbone, layered with diet, lifestyle, pelvic rehabilitation, and selected adjunctive therapies to address the full range of symptom drivers. ^[1,6]

At Direct Integrative Care, we use functional medicine as a clinical framework for organizing individualized, adjunctive care—not as a replacement for evidence-based endometriosis management. This article reviews the current evidence across each domain, acknowledges where it remains limited, and offers a practical approach for clinicians and clients navigating the integrative landscape.

Pathophysiology: Why Functional Medicine Has Legitimate Terrain

Understanding why functional medicine is relevant requires appreciating that endometriosis pain is not purely anatomical. Several interconnected pathological mechanisms are at play, each representing a modifiable intervention target.

Chronic inflammation and NF-κB signaling

Endometriotic lesions generate a self-sustaining inflammatory microenvironment. Ectopic tissue activates macrophages and mast cells, producing prostaglandins (PGE2), pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), and reactive oxygen species (ROS). The NF-κB signaling pathway is constitutively overactivated in endometriotic tissue, serving as a central node that promotes lesion growth, angiogenesis via VEGF upregulation, and fibrosis. Oxidative stress—measured as elevated total oxidant status (TOS), reduced superoxide dismutase (SOD), and depleted glutathione—amplifies the inflammatory cascade and damages peritoneal mesothelial cells, facilitating implantation of ectopic tissue. ^[1] This mechanistic landscape is precisely what makes anti-inflammatory, antioxidant, and NF-κB-modulating interventions biologically plausible.

Estrogen dependence and the estrobolome

Endometriosis is fundamentally estrogen-dependent: ectopic lesions express aromatase (CYP19A1) and generate local estradiol, which promotes lesion persistence independent of ovarian production. Beyond ovarian and local estrogen synthesis, a critical and under-appreciated pathway involves the estrobolome—the aggregate of gut bacterial genes whose enzyme products, especially β-glucuronidase, metabolize estrogens. In the hepatic phase II conjugation pathway, estrogens are glucuronidated for fecal excretion. When gut β-glucuronidase activity is elevated due to dysbiosis, these conjugated estrogens are deconjugated and reabsorbed through enterohepatic recycling, raising total circulating estrogen exposure. ^[11]

A 2023 case-control study profiling the gut microbiome–estrobolome in reproductive-age women found that fecal samples from endometriosis clients had significantly higher folds of several estrogen metabolites—estriol, 16-epiestriol, 16α-hydroxyestrone, and 2-methoxyestradiol—despite no gross difference in β-glucuronidase activity or overall microbial diversity. ^[11] A 2025 PROSPERO-registered systematic review confirmed that gut dysbiosis and estrobolome alterations are consistently observed in endometriosis. This provides the mechanistic rationale for interventions targeting bowel regularity, fiber intake, probiotic diversity, and endocrine-disruptor avoidance.

Estrogen metabolism: the 2-OH/4-OH/16-OH pathway

Beyond total estrogen load, the pattern of estrogen metabolism may influence disease activity. Estradiol (E2) and estrone (E1) undergo phase I hydroxylation via cytochrome P450 enzymes into three primary metabolite families:

• 2-hydroxyestrone (2-OH): Catalyzed primarily by CYP1A1/CYP1A2. Considered the “protective” pathway—these metabolites are weak estrogen-receptor binders with antiproliferative and antioxidant properties.
• 4-hydroxyestrone (4-OH): Catalyzed by CYP1B1. This is the “genotoxic” pathway—these metabolites can form reactive quinones that generate DNA adducts, particularly if phase II methylation by COMT is insufficient. CYP1B1 is overexpressed in many hormonally driven tumors and in ectopic endometrial tissue.
• 16α-hydroxyestrone (16-OH): The “proliferative” pathway. 16-OH metabolites bind estrogen receptors irreversibly and promote cell growth, and have been associated with tissue proliferation in fibroids and endometriosis.

Phase II detoxification then processes these metabolites through methylation (COMT enzyme, requiring magnesium, SAMe, and B vitamins as cofactors), sulfation (SULT enzymes), and glucuronidation (UGT enzymes) for excretion. The clinical implications are significant: interventions that shift the balance toward the 2-OH pathway (such as DIM/I3C from cruciferous vegetables), support COMT methylation (magnesium, methylfolate, B12), or enhance glucuronidation and excretion (fiber, calcium-D-glucarate) may reduce the net estrogenic and genotoxic burden on ectopic tissue. DUTCH testing or urinary estrogen metabolite panels can characterize these ratios in individual clients, though clinical guidelines for interpretation remain evolving.

The estrogen–mast cell–histamine feedback loop

One of the most clinically underappreciated mechanisms in endometriosis is the bidirectional cross-talk between estrogen and mast cells. Endometriotic lesions harbor significantly higher numbers of activated, degranulated mast cells compared to matched eutopic endometrium, along with elevated stem cell factor (SCF)—the key growth factor for mast cell recruitment and differentiation. ^[13] The endometriotic microenvironment upregulates genes (CPA3, VCAM1, CCL2, CMA1, KITLG) that are conducive to mast cell recruitment and maturation.

Upon activation, mast cells release histamine, tryptase, TNF-α, IL-6, PGE2, and fibroblast growth factor 2 (FGF2). This creates a positive feedback loop: estrogen activates mast cells → mast cells release histamine and inflammatory mediators → histamine stimulates aromatase and estrogen synthesis → elevated estrogen further activates mast cells. Clinically, elevated histamine has been detected in both peripheral blood and endometriotic lesions, and blocking histamine receptors with H1-antihistamines has been shown to reduce pain symptoms in some clients. A 2025 gene-regulation study further supported the therapeutic potential of H1-antihistamines in endometriosis due to their anti-inflammatory and mast-cell-stabilizing properties. ^[15]

This feedback loop is particularly relevant for clients with concurrent mast cell activation syndrome (MCAS) or histamine intolerance, conditions that commonly overlap with endometriosis and share symptoms including bloating, flushing, urticaria, anxiety, and food intolerances. The practical implication: managing histamine load—through low-histamine dietary strategies, DAO enzyme support, mast cell stabilizers (quercetin, luteolin), and antihistamines—may provide meaningful symptom relief for this subpopulation. ^[13]

Central sensitization and nociplastic pain

Prolonged nociceptive input from endometriotic lesions sensitizes dorsal horn neurons, producing central sensitization (CS)—a state of amplified pain processing that manifests as hyperalgesia, allodynia, and pain that persists even after lesion removal. A 2024 scoping review identified CS as the primary nociplastic pain mechanism in endometriosis and catalogued over 30 assessment tools for detecting it. ^[10]

This is clinically critical: if CS is not addressed, surgery may excise lesions without resolving pain. CS also explains the high comorbidity of endometriosis with IBS, interstitial cystitis/painful bladder syndrome, vulvodynia, fibromyalgia, temporomandibular disorder, and migraine—conditions that share altered central pain processing. Mast cell degranulation products (histamine, tryptase, FGF2) directly enhance peripheral pain signaling and drive central sensitization through elevated responsiveness of dorsal horn neurons, forming a neuroimmune feedback loop between mast cells, nerve fibers, and the CNS. ^[10,13]

The triad of chronic inflammation, estrogen excess (including the mast cell–histamine axis), and central sensitization defines the terrain where functional medicine has legitimate, evidence-informed roles to play.

Dietary Interventions: What the Evidence Shows

There is no single “best” diet for endometriosis. A 2024 meta-analysis of RCTs confirmed benefit for dietary intervention as an adjunct but underscored methodological limitations. ^[4] A Mediterranean-style, anti-inflammatory dietary pattern appears the most reasonable and lowest-risk foundation—and is the only specific pattern with sufficient safety data to recommend without nutritional concerns. ^[2]

Mediterranean and anti-inflammatory diet

The Mediterranean pattern—rich in vegetables, fruits, whole grains, legumes, fatty fish, olive oil, nuts, and seeds—delivers a high antioxidant and omega-3 load while limiting red meat, ultra-processed foods, and refined sugars. This pattern provides substrates that compete with pro-inflammatory omega-6 pathways and downregulates NF-κB signaling. The cruciferous vegetable component (broccoli, kale, Brussels sprouts, cauliflower) delivers indole-3-carbinol (I3C) and its metabolite diindolylmethane (DIM), which promote favorable 2-OH estrogen metabolism. Review-level evidence supports anti-inflammatory dietary patterns for endometriosis symptom management, though no single diet has been proven definitive. ^[1,2]

Low-FODMAP strategies

IBS-type symptoms—bloating, gas, altered bowel habits—coexist in a large proportion of endometriosis clients, with up to 90% reporting GI symptoms. When these dominate, a time-limited low-FODMAP approach (4–6 weeks) followed by structured reintroduction can meaningfully reduce GI symptom burden. However, prolonged low-FODMAP restriction increases lipopolysaccharide (LPS) exposure, reduces beneficial bifidobacteria and butyrate-producing bacteria, and depletes short-chain fatty acid (SCFA) production—all counterproductive to the gut-estrogen axis. The goal is to identify individual triggers through reintroduction, not to create a long-term restrictive pattern. ^[1]

Red meat, dairy, alcohol, and soy

Higher red-meat intake has been associated with elevated circulating sex hormones and prostaglandins in observational studies. Dairy may increase serum estrogen, progesterone, and IGF-1. Alcohol impairs hepatic estrogen clearance. Soy phytoestrogens present a nuanced picture: their weak estrogen-receptor binding may be anti-estrogenic in a high-estrogen environment (competitive inhibition) but estrogenic in a low-estrogen environment. These associations are biologically plausible but derived largely from observational data, not randomized trials in endometriosis populations. The practical recommendation is moderation guided by individual symptom tracking, not blanket elimination. ^[1]

Fiber, the estrobolome, and bowel regularity

Adequate dietary fiber (targeting 25–35 g/day from whole-food sources) has a dual role. First, regular bowel movements reduce enterohepatic estrogen recycling by limiting the time conjugated estrogens spend in the colon exposed to bacterial β-glucuronidase. Second, prebiotic fibers (inulin, resistant starch, pectin, beta-glucans) feed beneficial gut commensals that produce short-chain fatty acids (SCFAs)—particularly butyrate—which support intestinal barrier integrity, modulate immune responses, and may restrain the pro-inflammatory peritoneal microenvironment. Fermented foods (sauerkraut, kimchi, kefir, miso) complement fiber by providing live probiotic organisms that enhance microbial diversity. ^[1,11]

Anti-histamine and low-histamine dietary considerations

For the subpopulation of endometriosis clients with concurrent MCAS or histamine intolerance, dietary histamine management becomes relevant. Histamine-rich foods (aged cheeses, cured meats, fermented foods, alcohol, leftover proteins) and DAO-inhibiting substances (alcohol, certain medications) can amplify the estrogen–mast cell–histamine feedback loop. A time-limited low-histamine trial may be diagnostic and therapeutic, though—as with low-FODMAP—long-term restriction should be avoided because many high-histamine foods (fermented foods) are otherwise beneficial for the microbiome. This tension must be navigated individually. ^[13,15]

Supplements: An Evidence-Stratified Approach

The supplement landscape for endometriosis is marked by biologically plausible mechanisms but inconsistent or limited clinical trial evidence. The most honest approach is to stratify supplements by evidence quality, individualize based on symptoms and labs, and avoid presenting any stack as a proven protocol. Below, each supplement includes its mechanism, the best available evidence, an evidence-quality rating, and practical dosing guidance. ^[4,6]

Omega-3 fatty acids (EPA/DHA)

Mechanism: Omega-3 PUFAs compete with arachidonic acid for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, shifting prostaglandin synthesis from the pro-inflammatory PGE2/PGF2α series toward less inflammatory resolvins and protectins. They also suppress NF-κB activation and reduce TNF-α and IL-6 production.

Evidence: A meta-analysis of five RCTs (n=424) found that omega-3 supplementation improved pain outcomes. A 2024–2025 cohort study reported that adjunctive omega-3 intake was associated with reduced VAS pain scores, lower IL-6 and TNF-α, improved CRP, and better health-related quality of life (SF-36 PCS and MCS). ^[1,4]

Evidence quality: Moderate (multiple RCTs, supportive meta-analysis). Dosing: 2–4 g combined EPA+DHA daily; quality and third-party testing (IFOS) matter. Triglyceride or phospholipid forms preferred for bioavailability.

N-Acetylcysteine (NAC)

Mechanism: NAC is the rate-limiting precursor for glutathione synthesis—the body’s master antioxidant. It also has direct anti-inflammatory, antiproliferative, and anti-angiogenic effects on endometriotic tissue. In-vitro and metabolomic work demonstrates that NAC disrupts the Warburg effect, citric acid cycle, glutathione metabolism, and mitochondrial electron transport chain in endometriotic cells, triggering apoptosis and reducing locomotor behavior of ectopic cells.

Evidence: The landmark Italian observational study (n=92 women, 145 endometriomas) found that after 3 months, NAC-treated clients showed a slight reduction in mean cyst diameter (−1.5 mm) versus a significant increase (+6.6 mm) in untreated controls (P=0.001). Twenty-four NAC-treated clients cancelled scheduled laparoscopy due to cyst decrease/disappearance or pain reduction, versus only one control. A 2023 prospective single-cohort study replicated these findings. ^[7,8]

Evidence quality: Moderate-to-low (observational + single-cohort; no blinded RCT yet). NAC’s excellent safety profile and near-zero toxicity make it a reasonable option, particularly for clients who are symptomatic and awaiting or declining surgery, or when fertility preservation is a goal. Dosing: 600 mg × 3, three consecutive days per week, for 3+ months (the protocol used in the major studies).

Curcumin

Mechanism: Curcumin inhibits NF-κB activation, suppresses VEGF-mediated angiogenesis, reduces COX-2 and inflammatory cytokine production, and promotes apoptosis of ectopic endometrial cells. It also modulates the NLRP3 inflammasome, reduces MAPK/ERK phosphorylation, and decreases MMP expression (metalloproteinases that facilitate tissue invasion). Animal studies consistently show reductions in ectopic implant volume.

Evidence: A 2023 triple-blind RCT demonstrated significant reduction in endometriosis pain symptoms with curcumin versus placebo. A 2024–2025 RCT tested curcumin as an add-on to dienogest and reported additional benefit in pain and inflammatory biomarkers beyond dienogest alone. ^[1,4]

Evidence quality: Moderate (RCT evidence emerging, strong preclinical rationale). Key limitation: Standard curcumin has extremely low oral bioavailability (<1% absorption). Clinical use requires enhanced formulations: phytosomal (Meriva), lipid-nanoparticle, or piperine-complexed preparations. Dosing: 500–1000 mg of a bioavailability-enhanced curcumin preparation, twice daily with food.

Vitamins C and E (antioxidant pair)

Mechanism: Vitamins C and E address oxidative stress—a well-documented feature of the endometriotic peritoneal environment. Vitamin E is lipid-soluble and protects cell membranes; vitamin C regenerates oxidized vitamin E and scavenges aqueous-phase ROS. Together they reduce oxidative damage that promotes lesion implantation and pain signaling.

Evidence: A 2024 meta-analysis of five RCTs found that combined supplementation was associated with markedly higher proportion of clients reporting reduced chronic pelvic pain (RR 7.30; 95% CI: 3.27–16.31), reduced dysmenorrhea (RR 1.96), and reduced dyspareunia (RR 5.08). ^[9]

Evidence quality: Moderate (multiple RCTs with consistent direction; effect sizes are large enough to warrant cautious interpretation given small study sizes). Dosing: Vitamin C 1000 mg + vitamin E 800 IU daily (the regimen used in the major trials). Use mixed tocopherols rather than synthetic dl-alpha-tocopherol.

Alpha-lipoic acid (ALA)

Mechanism: ALA is both water- and lipid-soluble, regenerates vitamins C and E, chelates redox-active metals, and enhances mitochondrial function. In an experimental rat model, ALA significantly reduced endometrial implant volumes, TNF-α in peritoneal fluid, total oxidant status (TOS), and histopathologic severity scores.

Evidence: The LEAP study—a multicenter, open-label trial of 398 endometriosis clients—found that a combination of NAC, alpha-lipoic acid, and bromelain taken for 6 months produced significant reduction in pelvic pain (92.7% with moderate/severe pain at baseline vs. 82.7% at 6 months, P<0.05) and decreased rescue analgesic use. This study is notable because it specifically enrolled women who wished to become pregnant, demonstrating a fertility-compatible option. ^[14]

Evidence quality: Low-to-moderate (animal data + one open-label trial with a combination product). Dosing: 300–600 mg ALA daily (R-lipoic acid form preferred for bioactivity).

Vitamin D

Mechanism: Vitamin D modulates immune function (promotes tolerogenic dendritic cells, suppresses Th17 responses), inhibits inflammatory cytokine production, and may suppress endometriotic cell proliferation in vitro. Observational studies frequently find lower 25(OH)D levels in women with endometriosis.

Evidence: Clinical trial evidence for supplementation’s impact on endometriosis-specific pain is mixed. A 2022 systematic review found no significant effect on dysmenorrhea or non-cyclic pelvic pain. A 2025 systematic review of registered RCTs noted methodological heterogeneity and called for larger, well-designed trials. ^[12]

Evidence quality: Low for endometriosis-specific pain outcomes; strong for general immune health. Clinical approach: Test 25(OH)D and correct deficiency (target 40–60 ng/mL) because of vitamin D’s broad immunomodulatory role, but do not promise endometriosis-specific pain relief. Dosing: 2000–5000 IU daily, adjusted by lab monitoring; take with fat-containing meals for absorption.

Magnesium

Mechanism: Magnesium modulates smooth-muscle contraction (uterine and pelvic floor), pain signaling (NMDA receptor antagonism), HPA axis regulation, and—critically for endometriosis—serves as a required cofactor for COMT (catechol-O-methyltransferase), the enzyme responsible for methylating and detoxifying 2-OH and 4-OH estrogen metabolites in phase II metabolism. Magnesium deficiency impairs COMT function, potentially allowing accumulation of genotoxic 4-OH catechol estrogens. Deficiency is common in the general population, and menstrual blood loss further increases requirements.

Evidence quality: Low for endometriosis specifically; moderate for general dysmenorrhea and COMT support. Dosing: 200–400 mg elemental magnesium daily. Glycinate is preferred for absorption and anxiolytic effects; threonate for CNS penetration; citrate for constipation-prone clients.

DIM (Diindolylmethane) and I3C (Indole-3-Carbinol)

Mechanism: DIM is the stable, bioactive metabolite of I3C—derived from cruciferous vegetables. DIM promotes the 2-hydroxylation pathway of estrogen metabolism (via CYP1A1 upregulation), shifting the 2-OH:16-OH ratio in a favorable direction and reducing aromatase activity. A 2024 study using dried urine estrogen metabolite testing confirmed that DIM supplementation significantly increased the 2-hydroxyestrone:16-hydroxyestrone ratio in premenopausal women. In a small pilot, DIM combined with dienogest reduced pelvic pain and improved bleeding patterns compared to dienogest alone.

Evidence quality: Low (small pilot + mechanistic data; no endometriosis-specific RCT). The physiological rationale is sound, but clinical proof in endometriosis remains preliminary. DIM is generally preferred over I3C because I3C is unstable and can produce unwanted byproducts in acidic gastric conditions. Dosing: 100–200 mg DIM daily (microencapsulated/bioenhanced form); higher doses can paradoxically activate estrogen receptors.

Quercetin and luteolin (mast cell stabilizers)

Mechanism: Quercetin and luteolin are flavonoids with dual anti-inflammatory and mast-cell-stabilizing properties. They inhibit mast cell degranulation, suppress histamine release, block NF-κB activation, and reduce IL-6, IL-8, and TNF-α production. Quercetin also inhibits proliferation of endometriotic cells and suppresses MMP-2 and MMP-9 expression in vitro. For clients with the estrogen–mast cell–histamine phenotype, these represent mechanistically targeted interventions. ^[13,15]

Evidence quality: Very low for endometriosis specifically (preclinical only); moderate for mast cell stabilization broadly. Dosing: Quercetin 500–1000 mg daily in divided doses; luteolin 100–200 mg daily. Take with bromelain to enhance absorption.

Probiotics and prebiotic strategies

Given the gut–estrogen connection via the estrobolome, probiotic and prebiotic strategies have strong theoretical appeal. Multi-strain probiotics may improve microbial diversity, reduce systemic inflammation via SCFA production, and modulate estrogen metabolism. However, no endometriosis-specific probiotic strain or formulation has been validated in clinical trials. The most defensible approach is to support gut diversity primarily through diet (30+ plant foods per week, fermented foods) and to use multi-strain probiotics strategically when dysbiosis, antibiotic disruption, or post-surgical recovery is clinically relevant. ^[1,11]

Evidence quality: Very low for endometriosis; conceptual and preclinical. Strains of interest: Lactobacillus and Bifidobacterium species for general gut diversity; avoid high-histamine probiotic strains (L. casei, L. bulgaricus) in MCAS-overlap clients.

Other supplements of interest

Resveratrol (anti-inflammatory, anti-angiogenic in animal models via VEGF and MMP suppression; no human endometriosis RCTs). EGCG/green tea polyphenols (anti-angiogenic; reduced endometriotic lesion size in murine models). Zinc (immune modulation, antioxidant; deficiency associated with increased endometriosis risk observationally). Folate/methylfolate and B12 (cofactors for COMT-mediated estrogen methylation; critical for phase II detoxification). Calcium-D-glucarate (inhibits bacterial β-glucuronidase in the gut, theoretically reducing estrogen reabsorption; no endometriosis-specific trials). Selenium (supports glutathione peroxidase activity; observational data only). ^[1,4] For each, the evidence base is preclinical or derived from small, unblinded studies. These may be individualized based on symptom profile and lab findings but should not be framed as proven treatments.

Iron Deficiency: The Overlooked Comorbidity

Heavy menstrual bleeding (menorrhagia) is one of the most common symptoms of endometriosis and adenomyosis, yet iron deficiency is consistently under-screened. Chronic iron depletion produces fatigue, brain fog, exercise intolerance, restless legs, cold intolerance, hair thinning, and worsened anxiety/depression—symptoms that overlap with and amplify endometriosis-related disability. Ferritin should be checked in every endometriosis client, and optimal repletion targets (ferritin >50–70 ng/mL, not merely >12 ng/mL) should guide supplementation. Iron bisglycinate is generally preferred for tolerability; IV iron infusion is indicated for severe deficiency or GI intolerance. Vitamin C co-administration enhances non-heme iron absorption.

Endocrine Disruptors and Environmental Toxin Avoidance

Reviews note plausible links between endocrine-disrupting chemicals (EDCs) and endometriosis, with evidence strongest for persistent organic pollutants (PCBs, dioxins), phthalates, and bisphenol A (BPA). A meta-analysis of 30 epidemiological studies found an overall odds ratio of 1.41 (95% CI: 1.23–1.60) for the association between EDC exposure and endometriosis. While this is epidemiological association rather than proven causation, the precautionary principle supports reasonable avoidance strategies: ^[2]

• Filter drinking water (activated carbon or reverse osmosis)
• Minimize plastic food storage; use glass or stainless steel, especially for hot foods and liquids
• Choose fragrance-free personal care and cleaning products (phthalates are common fragrance carriers)
• Reduce thermal paper receipt handling (BPA/BPS exposure)
• Choose organic produce where feasible, prioritizing the EWG “Dirty Dozen” list for pesticide avoidance
• Avoid heating food in plastic containers or plastic wrap

These measures are low-cost, low-risk, and align with the broader functional medicine principle of reducing total toxicant burden.

Pelvic Floor Rehabilitation and Body-Based Therapies

Pelvic floor physical therapy (PFPT)

Chronic pelvic pain in endometriosis frequently involves secondary pelvic floor dysfunction: hypertonic muscles, myofascial trigger points, guarding patterns, and altered motor recruitment that perpetuate pain independent of lesion activity. PFPT addresses these through internal manual therapy, myofascial release, trigger-point treatment, biofeedback, graded motor retraining, and visceral mobilization. A 2025 RCT demonstrated that supervised exercise combined with pelvic floor muscle training reduced current pelvic and genital pain in women with confirmed endometriosis. PFPT is recommended for any client with dyspareunia, dyschezia, or pain persisting after medical/surgical treatment—as these may reflect CS and myofascial dysfunction rather than active disease. ^[3,5]

Acupuncture

Meta-analyses report improved pain scores for dysmenorrhea and chronic pelvic pain, reduced serum CA-125, decreased nodule size, and improved quality of life—with effects potentially mediated through endogenous opioid release, prostaglandin modulation, and parasympathetic activation. Moxibustion combined with acupuncture shows improved scores versus conventional therapies alone. The principal limitation is that original study quality is often low with high risk of bias. Acupuncture carries essentially no adverse effects and may be especially useful for clients declining or poorly tolerating hormonal therapy. ^[3,5]

Exercise, yoga, and movement

A 2024–2025 meta-analysis confirmed benefit for pain and quality of life, with yoga and holistic mind–body programs showing the strongest evidence. Exercise modulates inflammation (reducing CRP, TNF-α), improves mood, supports bowel motility, and may reduce CS through descending inhibitory pathways. The key is consistency without overtraining: excessive high-intensity exercise paradoxically increases cortisol and inflammation. A program combining regular moderate aerobic activity (150 min/week), yoga or Pilates (2–3 sessions/week), and targeted pelvic floor work is a reasonable starting framework. ^[2]

TENS

Transcutaneous electrical nerve stimulation improves deep dyspareunia and reduces pain days. As a non-invasive, home-based modality, TENS is a practical adjunct for clients managing chronic pelvic pain, particularly between or awaiting interventions. ^[5]

Mind–Body Therapies, Sleep, and HPA Axis Support

Central sensitization amplifies endometriosis pain beyond what lesion burden predicts. Therapies targeting the nervous system and psychological dimensions are not optional add-ons—they are core components. ^[10]

CBT and pain neuroscience education

CBT has the strongest evidence base for chronic pain broadly. In endometriosis, CBT and pain catastrophizing interventions address cognitive-affective dimensions that independently predict pain severity and post-surgical pain persistence. Pain neuroscience education—explaining CS in accessible terms—reduces fear-avoidance, improves self-efficacy, and reduces healthcare utilization in broader chronic pain populations. No adverse effects. ^[3,10]

Mindfulness-based stress reduction (MBSR)

MBSR, progressive muscle relaxation, guided imagery, and yoga nidra activate parasympathetic pathways that counteract chronic sympathetic dominance. Over 93% of endometriosis clients in one cross-sectional survey utilized at least one psychological management strategy, highlighting the demand for evidence-informed options. ^[3,5]

Sleep optimization

Sleep disruption is independently associated with pain amplification (lowered pain thresholds), immune dysregulation (elevated IL-6, reduced NK cell activity), and HPA axis dysregulation. Sleep deprivation also impairs hepatic estrogen clearance. Practical sleep hygiene—consistent sleep/wake times, cool dark environment, limiting blue light 60–90 minutes before bed, addressing sleep-disordered breathing—is a high-yield, zero-cost intervention. Magnesium glycinate (200–400 mg at bedtime) and melatonin (0.5–3 mg) can be adjuncts; melatonin also has direct anti-inflammatory and antioxidant properties in the peritoneal cavity.

HPA axis and stress regulation

Chronic stress and HPA axis dysregulation perpetuate the inflammatory state through elevated cortisol’s paradoxical pro-inflammatory effects at chronically elevated levels, impaired mucosal immunity, increased intestinal permeability (“leaky gut”), and disrupted estrogen metabolism. Adrenal adaptogens (ashwagandha, rhodiola) have general evidence for stress resilience but no endometriosis-specific trials. The most evidence-based approach is consistent stress-modulation practices: yoga, MBSR, diaphragmatic breathing, regular moderate exercise, and adequate sleep.

The Functional Workup: What to Assess and Why

A functional medicine workup systematically identifies the modifiable factors amplifying symptom burden in each individual client. This does not replace the gynecologic workup (pelvic exam, transvaginal ultrasound, pelvic MRI, laparoscopy)—it runs in parallel.

Laboratory assessment

• Inflammatory markers: hs-CRP, ESR (baseline inflammation), ferritin (dual role: iron status and acute phase reactant).
• Iron panel: Serum ferritin, serum iron, TIBC, transferrin saturation. Target ferritin >50–70 ng/mL for optimal oxygen delivery and energy.
• Vitamin D: 25(OH)D. Target 40–60 ng/mL.
• Magnesium: RBC magnesium (serum magnesium is insensitive). Target >5.0 mg/dL.
• B vitamins: B12, folate, methylmalonic acid, homocysteine (the latter two as functional markers of B12 and folate adequacy for methylation).
• Zinc: Serum or RBC zinc.
• Thyroid panel: TSH, free T4, free T3, TPO and TG antibodies (autoimmune thyroiditis co-occurs at higher rates).
• Estrogen metabolites (selected cases): DUTCH Complete or urinary estrogen metabolite panel to characterize 2-OH:4-OH:16-OH ratios, methylation adequacy (2-OHE1:2-MeOE1 ratio), and cortisol patterns. Most useful when considering DIM, methylation support, or COMT-targeting interventions.
• SIBO breath testing: If bloating, gas, and IBS-type symptoms are refractory to dietary change.

Clinical assessment

• Symptom tracking: Pain timing, intensity, character; bowel symptoms; bleeding patterns; dyspareunia; sleep quality; responses to cycles, foods, stressors. Apps and structured diaries improve accuracy.
• Pelvic floor assessment: Internal exam by trained pelvic floor PT. Hypertonicity, trigger points, and myofascial patterns are distinct from lesion pain and require different treatment.
• Central sensitization screening: Widespread pain, comorbid pain syndromes (IBS, IC, migraine, fibromyalgia, TMD), allodynia on exam, Central Sensitization Inventory (CSI) questionnaire.
• Histamine/MCAS screening: Flushing, urticaria, GI reactivity to high-histamine foods, intermenstrual symptom flares, response to antihistamines. Serum tryptase, 24-hour urine N-methylhistamine, and prostaglandin metabolites where MCAS overlap is suspected.
• Mental health screening: PHQ-9, GAD-7. Depression and anxiety co-occur at significantly higher rates in endometriosis and require concurrent treatment.
• Coexisting conditions: Autoimmune thyroiditis, MCAS, PCOS, adenomyosis, interstitial cystitis, EDS/hypermobility (the latter disproportionately overlaps with both endometriosis and MCAS).

Fertility-Specific Considerations

When a client is trying to conceive, the integrative approach shifts in important ways:

• Hormonal suppression (progestins, GnRH agonists/antagonists) is paused during active conception attempts, making the functional plan’s anti-inflammatory and hormone-modulating roles more central.
• NAC is particularly valuable: the original endometrioma studies showed cyst reduction without affecting fertility, and 8 pregnancies occurred in the NAC group. The LEAP study (NAC + ALA + bromelain) specifically enrolled fertility-desiring women. ^[7,14]
• Omega-3s are safe and encouraged preconceptionally and during pregnancy.
• Curcumin, DIM, and high-dose antioxidants should be discussed individually—some practitioners discontinue high-dose supplementation once conception is confirmed, while others continue lower maintenance doses through the first trimester.
• Iron repletion is critical: adequate ferritin supports implantation, placental development, and fetal growth.
• Vitamin D sufficiency (40–60 ng/mL) is associated with improved IVF outcomes and reduced miscarriage risk independent of endometriosis.
• The gut–estrogen axis matters more during unmedicated cycles: ensuring bowel regularity, fiber adequacy, and probiotic diversity helps manage estrogen load without pharmacological suppression.

Post-Surgical Integrative Support

Excision surgery remains the gold standard for definitive diagnosis and treatment of deep infiltrating endometriosis. However, surgery alone does not address the systemic drivers—inflammation, estrogen excess, central sensitization, pelvic floor dysfunction—that contribute to recurrence (estimated at 20–50% within 5 years). A post-surgical integrative protocol may include:

• Continued anti-inflammatory nutrition and targeted supplementation
• Pelvic floor PT beginning 4–6 weeks post-operatively (or sooner with surgeon clearance) to address post-surgical adhesions, guarding patterns, and hypertonic remodeling
• Pain neuroscience education and CBT if pre-operative central sensitization was identified
• Gut restoration: broad-spectrum probiotics and prebiotic fiber, particularly if perioperative antibiotics were given
• Hormonal suppression (dienogest, progesterone IUD, or combined OCP) per gynecologic recommendation to reduce recurrence risk
• Scar mobilization and visceral osteopathy for adhesion-related pain

A Practical Clinical Framework

1. Start with symptom tracking. Map pain timing, intensity, character; bowel symptoms; bleeding patterns; dyspareunia; sleep quality; responses to cycles, foods, stressors. Apps and structured diaries improve accuracy and reduce recall bias. ^[1]
2. Build the anti-inflammatory base. Mediterranean-style nutrition emphasizing omega-3–rich foods, cruciferous vegetables, fiber (25–35 g/day), and fermented foods. Adequate sleep (7–9 hours), consistent moderate exercise (150 min/week), and stress-modulation practices (yoga, MBSR, breathwork). ^[2]
3. Correct nutritional deficits. Test and replete iron (ferritin target >50–70), vitamin D (target 40–60 ng/mL), magnesium, zinc, and B vitamins based on labs. Address overt GI dysfunction (constipation, SIBO, dysbiosis). ^[1,12]
4. Add targeted supplements. Omega-3s (2–4 g EPA+DHA), curcumin (bioavailability-enhanced form), NAC (600 mg × 3, three days/week), vitamins C+E, DIM (100–200 mg), and/or ALA—based on symptoms, goals, and tolerance. Start one at a time when possible, with defined trial periods (8–12 weeks) and outcome tracking. ^[4,7,8,9,14]
5. Address the mast cell–histamine phenotype if present. Low-histamine dietary trial, quercetin/luteolin, DAO enzyme support, and H1/H2 antihistamines in clients with concurrent MCAS, histamine intolerance, or prominent flushing/urticaria/food reactivity. ^[13,15]
6. Support estrogen detoxification. DIM or cruciferous-rich diet for 2-OH pathway support; methylation cofactors (magnesium, methylfolate, B12) for COMT; fiber and calcium-D-glucarate for intestinal estrogen excretion; environmental toxin avoidance for EDC burden reduction.
7. Engage body-based therapies. Pelvic floor PT referral, acupuncture (especially for clients declining or failing hormonal therapy), TENS for home-based pain management. ^[3,5]
8. Address central sensitization. Pain neuroscience education, CBT, MBSR, graded motor imagery. Screen for comorbid pain syndromes and manage them as interconnected, not separate, conditions. ^[10]
9. Optimize sleep and stress regulation. Sleep hygiene, magnesium glycinate at bedtime, melatonin if needed, consistent stress-modulation practices.
10. Escalate and integrate standard care as needed. Hormonal suppression, fertility evaluation, or excision surgery depending on severity, stage, and reproductive goals. The functional plan runs in parallel—it does not gate-keep conventional treatment. ^[1,6]

Clinical Caution: What We Know, What We Don’t

• No supplement or diet has been proven to cure endometriosis, prevent lesion recurrence, or replace surgery where excision is indicated.
• Many of the most commonly cited supplements are supported by preclinical data, observational studies, or small trials with high risk of bias. Promising is not the same as proven.
• The newest scoping reviews (2024–2025) are encouraging for integrative symptom support, yet they consistently call for higher-quality RCTs before any specific “natural protocol” can be considered standard of care. ^[6]
• Central sensitization may explain why some clients report persistent or worsening pain despite “doing everything right”—and it requires nervous-system-targeted care, not more supplements. ^[10]
• The estrobolome hypothesis and the mast cell–histamine axis are mechanistically compelling but remain in early clinical validation. ^[11,13]
• Individual variation is enormous. What works for one phenotype (inflammatory-dominant with GI symptoms) may be irrelevant for another (CS-dominant with myofascial pain). This is why cookie-cutter supplement stacks are inappropriate.

The honest, defensible position is to combine the strongest available conventional treatment with the lowest-risk, best-supported integrative adjuncts, individualized to each client’s symptom phenotype, goals, and lab findings—and to revisit the plan as the evidence evolves.

References

1. Abulughod N, Valakas S, El-Assaad F. Dietary and Nutritional Interventions for the Management of Endometriosis. Nutrients. 2024;16(23):3988. PMID: 39683382.
2. Lalla AT, Onyebuchi C, Jorgensen E, Clark N. Impact of lifestyle and dietary modifications for endometriosis development and symptom management. Curr Opin Obstet Gynecol. 2024;36(4):247-254. PMID: 38869435.
3. Mazur-Bialy AI, Tim S, et al. Holistic Approaches in Endometriosis—as an Effective Method of Supporting Traditional Treatment. Reprod Sci. 2024;31(11):3257-3274. PMID: 39043999.
4. Meneghetti JK, Pedrotti MT, et al. Effect of Dietary Interventions on Endometriosis: A Systematic Review and Meta-Analysis of RCTs. Reprod Sci. 2024;31(12):3613-3623. PMID: 39358652.
5. Desai J, Strong S, Ball E. Holistic approaches to living well with endometriosis. F1000Research. 2024;13:359. PMID: 39649833.
6. van Keizerswaard J, et al. Bridging gaps in endometriosis care: a scoping review of CAIM for pain and quality of life. Minerva Obstet Gynecol. 2025 (online ahead of print). PMID: 41160417.
7. Porpora MG, et al. A promise in the treatment of endometriosis: an observational cohort study on ovarian endometrioma reduction by N-acetylcysteine. Evid Based Complement Alternat Med. 2013;2013:240702. PMID: 23737821.
8. Anastasi E, et al. Efficacy of NAC on Endometriosis-Related Pain, Size Reduction of Ovarian Endometriomas, and Fertility Outcomes. Int J Environ Res Public Health. 2023;20(6):4686. PMID: 36981606.
9. Bayu P, Wibisono JJ, Raimondo D. Vitamin C and E antioxidant supplementation may significantly reduce pain symptoms in endometriosis: SR and MA of RCTs. PLoS One. 2024;19(5):e0301867. PMID: 38820319.
10. Gentles A, et al. Nociplastic Pain in Endometriosis: A Scoping Review. J Clin Med. 2024;13(24):7521. PMID: 39768460.
11. Pai AHY, et al. Gut Microbiome–Estrobolome Profile in Reproductive-Age Women with Endometriosis. Int J Mol Sci. 2023;24(22):16301. PMID: 38003496.
12. Zhou IW, et al. Vitamin D for primary dysmenorrhea and endometriosis-related pain—A systematic review of registered RCTs. PLoS One. 2025;20(4):e0321393. PMID: 40257978.
13. McCallion A, et al. Estrogen mediates inflammatory role of mast cells in endometriosis pathophysiology. Front Immunol. 2022;13:961599. PMID: 36016927.
14. Lete I, et al. Effectiveness of an antioxidant preparation with N-acetyl cysteine, alpha lipoic acid and bromelain in the treatment of endometriosis-associated pelvic pain: LEAP study. Eur J Obstet Gynecol Reprod Biol. 2018;228:221-224. PMID: 29980396.
15. Mantha S, Gajendran N. Exploring the therapeutic potential of H1-antihistamines in endometriosis—A gene regulation-based perspective. Front Pharmacol. 2025;16 (online). PMC12312656.

All references above were verified against PubMed/NLM records at the time of writing.

About Dr. Kim

Dr. Yoon Hang “John” Kim is a board-certified Preventive Medicine physician with more than 20 years of experience in integrative and functional medicine. He completed an Osher Fellowship under Dr. Andrew Weil at the University of Arizona and holds board certifications in Preventive Medicine and Integrative/Holistic Medicine, along with UCLA medical acupuncture certification. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 3 books and more than 20 peer-reviewed articles.

Professional: www.yoonhangkim.com    |    Clinical: Direct Integrative Care